U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2011
587
Name Type Language
IPILIMUMAB
DASH   EMA EPAR   INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
ipilimumab [INN]
Common Name English
MDX-101
Code English
IPILIMUMAB [USAN]
Common Name English
BMS-734016
Code English
MDX010
Code English
IPILIMUMAB [EMA EPAR]
Common Name English
IPILIMUMAB [MI]
Common Name English
IMMUNOGLOBULIN G1, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN .KAPPA.-CHAIN, DIMER
Common Name English
IPILIMUMAB [PURPLE BOOK CDER]
Common Name English
IPILIMUMAB [MART.]
Common Name English
MDX-CTLA-4
Code English
IMMUNOGLOBULIN G1, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN .GAMMA.1-CHAIN), DISULPHIDE WITH HUMAN .KAPPA.-CHAIN, DIMER
Common Name English
IPILIMUMAB [VANDF]
Common Name English
Ipilimumab [WHO-DD]
Common Name English
YERVOY
Brand Name English
IPILIMUMAB [JAN]
Common Name English
BMS734016
Code English
MDX-010
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 595917
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
FDA ORPHAN DRUG 177703
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
EMA ASSESSMENT REPORTS YERVOY (AUTHORIZED: MELANOMA)
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
NCI_THESAURUS C129822
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
WHO-VATC QL01XC11
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
FDA ORPHAN DRUG 657418
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
FDA ORPHAN DRUG 445014
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
LIVERTOX NBK548335
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
NDF-RT N0000182635
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
NCI_THESAURUS C128036
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
FDA ORPHAN DRUG 545116
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
WHO-ATC L01XC11
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
FDA ORPHAN DRUG 317710
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
Code System Code Type Description
DRUG CENTRAL
4958
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
PRIMARY
JAPANESE REVIEW
YERVOY
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
PRIMARY APPROVE JULY 2015
INN
8568
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
PRIMARY
MESH
C508317
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
PRIMARY
DRUG BANK
DB06186
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
PRIMARY
NDF-RT
N0000182157
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
PRIMARY Increased T Lymphocyte Activation [PE]
MERCK INDEX
m6384
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
PRIMARY Merck Index
DAILYMED
6T8C155666
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
PRIMARY
LACTMED
Ipilimumab
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
PRIMARY
WIKIPEDIA
IPILIMUMAB
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
PRIMARY
IUPHAR
6888
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
PRIMARY
NDF-RT
N0000182634
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
PRIMARY CTLA-4-directed Antibody Interactions [MoA]
SMS_ID
100000092960
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
PRIMARY
EVMPD
SUB29397
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
PRIMARY
RXCUI
1094833
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
PRIMARY RxNorm
ChEMBL
CHEMBL1789844
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
PRIMARY
FDA UNII
6T8C155666
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
PRIMARY
NCI_THESAURUS
C2654
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
PRIMARY
CAS
477202-00-9
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
PRIMARY
USAN
QQ-65
Created by admin on Sat Dec 16 16:01:27 GMT 2023 , Edited by admin on Sat Dec 16 16:01:27 GMT 2023
PRIMARY
ACTIVE MOIETY
IPILIMUMAB
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966